The U.S. Food and Drug Administration on Tuesday issued draft guidance on how companies could win approval for gene-editing treatments tailored to individual patients with rare genetic diseases.
Some rare diseases are caused by mutations that differ from patient to patient, so one treatment cannot work for everyone with the condition. Today each patient-specific version of a gene-editing product is treated as a separate product needing its own license application, said Andrew Byrnes, who directs one of the FDA's gene therapy divisions, according to the trade publication Regulatory Focus. He called that approach “infeasible” and “not necessary.”
The draft would allow multiple versions, or variants, of a gene-editing product to be covered by a single biologics license application. Sponsors would set out an “individualized feature space” in advance, meaning the limits within which the product can vary. A new variant inside those limits would be treated as a manufacturing change, not a new product, if lab data show it has adequate safety and activity. It could then be added after approval without new clinical trials, the Department of Health and Human Services said.
The guidance is limited to products meant to treat a disease caused by a single gene, with known disease-causing variants, where each version is designed to achieve the same editing result, Regulatory Focus reported. It also covers manufacturing, safety testing, including for unintended genetic changes, and naming and labeling.
“This guidance represents a critical step forward in FDA's efforts to support the development of individualized therapies for patients with rare genetic diseases,” said Karim Mikhail, director of the FDA's Center for Biologics Evaluation and Research. Health Secretary Robert F. Kennedy Jr. said “families confronting rare genetic diseases deserve more treatment options, no matter how few patients share their diagnosis.”
The document is a draft and is not binding. The FDA is taking public comments on docket FDA-2026-D-11783 for 30 days after the guidance is published in the Federal Register.
HHS also said the Centers for Medicare & Medicaid Services will broaden its Cell and Gene Therapy Access Model beyond sickle cell disease. Under the voluntary model, CMS negotiates outcomes-based deals with drugmakers on behalf of state Medicaid programs. CMS plans to invite makers of therapies for other conditions to apply in the coming months.